Methohexital Sodium for Injection Recall Issued
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Avet Pharmaceuticals Inc. is recalling 4284 vials of Methohexital Sodium for Injection due to failed impurities specifications.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 8, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened The recall was initiated because the product failed impurities/degradation specifications.
Which Products Are Affected Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, NDC 23155-893-31, Lot # 7000612A, Exp. Date 1/2028. A total of 4284 vials are affected. The product was manufactured by OneSource Specialty Pharma Limited, Bengaluru, India, for Avet Pharmaceuticals Inc., East Brunswick, NJ. Distribution was nationwide within the United States.
What You Should Do Consumers and healthcare providers should follow instructions provided in the firm's notification letter regarding the affected lot.
Why This Matters This ongoing Class II recall involves a human prescription drug distributed across the United States.
Source FDA Recall Number D-0662-2026
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (818 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 8, 2026.
Frequently Asked Questions
Common questions about this FDA recall.